Effekte von Unternehmenskooperationen auf die Innovation in der Pharmaindustrie

Lade...
Vorschaubild
Dateien
Meng_Dipl.pdf
Meng_Dipl.pdfGröße: 457.68 KBDownloads: 733
Datum
2006
Autor:innen
Meng, Yan
Herausgeber:innen
Kontakt
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
DOI (zitierfähiger Link)
ArXiv-ID
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Open Access Green
Core Facility der Universität Konstanz
Gesperrt bis
Titel in einer weiteren Sprache
The Impact of Interfirm Cooperation on the Innovation of the Pharmaceutical Industry
Forschungsvorhaben
Organisationseinheiten
Zeitschriftenheft
Publikationstyp
Masterarbeit/Diplomarbeit
Publikationsstatus
Published
Erschienen in
Zusammenfassung

The cooperation between pharmaceutical companies - licensing, co-R&D, joint ventures and alliances has long been a feature of this sector. The traditional transaction cost theory and resource-based theory reason it with efficiency, risk/cost-sharing, access to new market, or complementary resources. These explanations are correct but not complete, because the globalization of knowledge has provided new chances and challenges for the firms.

The pharmaceutical sector is a knowledge-based sector. The discovery of new drugs needs knowledge from different disciplines. One company can not have all the essential knowledge. Through cooperation with other organizations, it can gain access to the external knowledge. Many firms change their innovation system from a closed model to the open innovation model, in which the internal and external knowledge are combined.

This paper examines the effects of cooperation on the innovation of pharmaceutical sector. A knowledge-based view will be proposed which regards knowledge as the strategic asset of a firm. Organizational capabilities are important for the integration of special knowledge and the development of new knowledge. In this paper the indirect effects instead of direct effects of cooperation on innovation will be assumed. The black box of innovation will be opened, which means the integration and transfer of knowledge between the partners. The absorptive capacity, complementary knowledge, trust and evolution of the alliances influence the integration of knowledge. Through literature research and an example of the alliance between Bayer HealthCare and Millennium pharmaceuticals four hypotheses will be developed.

Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
650 Management
Schlagwörter
Unternehmenskooperation, offene Innovation, Bayer AG, Millennium Pharmaceuticals, interfirm cooperation, open innovation, knowledge-based view, absorptive capacity
Konferenz
Rezension
undefined / . - undefined, undefined
Zitieren
ISO 690MENG, Yan, 2006. Effekte von Unternehmenskooperationen auf die Innovation in der Pharmaindustrie [Master thesis]
BibTex
@mastersthesis{Meng2006Effek-4312,
  year={2006},
  title={Effekte von Unternehmenskooperationen auf die Innovation in der Pharmaindustrie},
  author={Meng, Yan}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/4312">
    <dc:rights>terms-of-use</dc:rights>
    <dcterms:issued>2006</dcterms:issued>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/42"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-24T10:13:28Z</dc:date>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:abstract xml:lang="eng">The cooperation between pharmaceutical companies - licensing, co-R&amp;D, joint ventures and alliances has long been a feature of this sector. The traditional transaction cost theory and resource-based theory reason it with efficiency, risk/cost-sharing, access to new market, or complementary resources. These explanations are correct but not complete, because the globalization of knowledge has provided new chances and challenges for the firms.&lt;br /&gt;&lt;br /&gt;The pharmaceutical sector is a knowledge-based sector. The discovery of new drugs needs knowledge from different disciplines. One company can not have all the essential knowledge. Through cooperation with other organizations, it can gain access to the external knowledge. Many firms change their innovation system from a closed model to the open innovation model, in which the internal and external knowledge are combined.&lt;br /&gt;&lt;br /&gt;This paper examines the effects of cooperation on the innovation of pharmaceutical sector. A knowledge-based view will be proposed which regards knowledge as the strategic asset of a firm. Organizational capabilities are important for the integration of special knowledge and the development of new knowledge. In this paper the indirect effects instead of direct effects of cooperation on innovation will be assumed. The black box of innovation will be opened, which means the integration and transfer of knowledge between the partners. The absorptive capacity, complementary knowledge, trust and evolution of the alliances influence the integration of knowledge. Through literature research and an example of the alliance between Bayer HealthCare and Millennium pharmaceuticals four hypotheses will be developed.</dcterms:abstract>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/4312/1/Meng_Dipl.pdf"/>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/4312/1/Meng_Dipl.pdf"/>
    <dc:creator>Meng, Yan</dc:creator>
    <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/4312"/>
    <dc:contributor>Meng, Yan</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-24T10:13:28Z</dcterms:available>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/42"/>
    <dc:language>deu</dc:language>
    <dcterms:title>Effekte von Unternehmenskooperationen auf die Innovation in der Pharmaindustrie</dcterms:title>
    <dcterms:alternative>The Impact of Interfirm Cooperation on the Innovation of the Pharmaceutical Industry</dcterms:alternative>
    <dc:format>application/pdf</dc:format>
  </rdf:Description>
</rdf:RDF>
Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Kontakt
URL der Originalveröffentl.
Prüfdatum der URL
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Begutachtet
Diese Publikation teilen